5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure

Objective. The serotonin (5-HT) pathway was shown to play a role in pulmonary hypertension (PH), but its functions in right ventricular failure (RVF) remain poorly understood. The aim of the current study was to investigate the effects of Terguride (5-HT2A and 2B receptor antagonist) or SB204741 (5-HT2B receptor antagonist) on right heart function and structure upon pulmonary artery banding (PAB) in mice. Methods. Seven days after PAB, mice were treated for 14 days with Terguride (0.2 mg/kg bid) or SB204741 (5 mg/kg day). Right heart function and remodeling were assessed by right heart catheterization, magnetic resonance imaging (MRI), and histomorphometric methods. Total secreted collagen content was determined in mouse cardiac fibroblasts isolated from RV tissues. Results. Chronic treatment with Terguride or SB204741 reduced right ventricular fibrosis and showed improved heart function in mice after PAB. Moreover, 5-HT2B receptor antagonists diminished TGF-beta1 induced collagen synthesis of RV cardiac fibroblasts in vitro. Conclusion. 5-HT2B receptor antagonists reduce collagen deposition, thereby inhibiting right ventricular fibrosis. Chronic treatment prevented the development and progression of pressure overload-induced RVF in mice. Thus, 5-HT2B receptor antagonists represent a valuable novel therapeutic approach for RVF.

[1]  A. Dierich,et al.  Serotonin 2B receptor is required for heart development. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  F. Oakley,et al.  Serotonin paracrine signaling in tissue fibrosis☆☆☆ , 2013, Biochimica et biophysica acta.

[3]  J. Vonesch,et al.  Ablation of Serotonin 5-HT2B Receptors in Mice Leads to Abnormal Cardiac Structure and Function , 2001, Circulation.

[4]  M. Humbert,et al.  Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[5]  M. Humbert,et al.  Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis , 2002, European Respiratory Journal.

[6]  M. Humbert,et al.  High Plasma Serotonin Levels in Primary Pulmonary Hypertension: Effect of Long-Term Epoprostenol (Prostacyclin) Therapy , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Kohtaro Abe,et al.  The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. , 2009, Chest.

[8]  Y. Yazaki,et al.  Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. , 2003, Cardiovascular research.

[9]  J. Launay,et al.  Increased plasma serotonin in primary pulmonary hypertension. , 1995, The American journal of medicine.

[10]  M. Guglin,et al.  Right side of heart failure , 2012, Heart Failure Reviews.

[11]  C. Ventetuolo,et al.  WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. , 2012, Progress in cardiovascular diseases.

[12]  P. Gmeiner,et al.  Pharmacological Profile of 2-Bromoterguride at Human Dopamine D2, Porcine Serotonin 5-Hydroxytryptamine 2A, and α2C-Adrenergic Receptors, and Its Antipsychotic-Like Effects in Rats , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[13]  R. Horowski,et al.  Agonism at 5-HT2B receptors is not a class effect of the ergolines. , 2005, European journal of pharmacology.

[14]  V. Křen,et al.  Pergolide, terguride and N,N'-spacer-linked oligomers of both interact with 5-HT2A receptors of rat tail artery. , 2004, Physiological research.

[15]  N. Aikawa,et al.  Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats. , 1993, Cardiovascular research.

[16]  M. Gladwin,et al.  Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. , 2006, Circulation.

[17]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[18]  V. Setola,et al.  Serotonin and Angiotensin Receptors in Cardiac Fibroblasts Coregulate Adrenergic-Dependent Cardiac Hypertrophy , 2008, Circulation research.

[19]  M. Humbert,et al.  Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension , 2002, Nature Medicine.

[20]  H. Milting,et al.  Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. , 2009, Cardiovascular research.

[21]  W. Seeger,et al.  Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats , 2010, European Respiratory Journal.

[22]  J. Mialet-Perez,et al.  Role of serotonin 5-HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice , 2013, Journal of Neural Transmission.

[23]  J. Launay,et al.  Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. , 1990, The American journal of medicine.

[24]  I. Clay,et al.  Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression. , 2013, American journal of respiratory and critical care medicine.

[25]  K. Shyu.  Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure? , 2008, Circulation research.

[26]  F. Fan,et al.  Serotonin inhibits apoptosis of pulmonary artery smooth muscle cells through 5-HT2A receptors involved in the pulmonary artery remodeling of pulmonary artery hypertension , 2013, Experimental lung research.

[27]  R. P. Thompson,et al.  Serotonin Potentiates Transforming Growth Factor-beta3 Induced Biomechanical Remodeling in Avian Embryonic Atrioventricular Valves , 2012, PloS one.

[28]  F. Camanni,et al.  Diagnosis and Drug Therapy of Prolactinoma , 1996, Drugs.

[29]  R. Matthay,et al.  Cor Pulmonale: An Overview , 2003, Seminars in respiratory and critical care medicine.

[30]  R. Schermuly,et al.  Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction , 2012, Basic Research in Cardiology.

[31]  L. Monassier,et al.  Serotonin 5-HT2B Receptor Blockade Prevents Reactive Oxygen Species–Induced Cardiac Hypertrophy in Mice , 2008, Hypertension.

[32]  H. Ohira,et al.  Development of Monocrotaline-Induced Pulmonary Hypertension Is Attenuated by a Serotonin Receptor Antagonist , 2014, Lung.

[33]  L. Monassier,et al.  Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts , 2018 .

[34]  N. Press,et al.  Targeting the serotonin pathway for the treatment of pulmonary arterial hypertension. , 2013, Pharmacology & therapeutics.

[35]  L. Frumkin.  The Pharmacological Treatment of Pulmonary Arterial Hypertension , 2012, Pharmacological Reviews.

[36]  R. Schermuly,et al.  Are tyrosine kinase inhibitors the better serotonin inhibitors? , 2013, American journal of respiratory and critical care medicine.

[37]  B. Dahal,et al.  The Peroxisome Proliferator–Activated Receptor β/δ Agonist GW0742 has Direct Protective Effects on Right Heart Hypertrophy , 2013, Pulmonary circulation.